Trial NCT03026803

View at ClinicalTrials.gov 
Org. Study IDs: 05195

Last trial update was posted on 2017-04-13

MeSH Interventions

Capecitabine Oxaliplatin

MeSH Conditions

Carcinoma, Hepatocellular Liver Neoplasms

Other Conditions

Hepatocellular Cancer Liver Cancer

Stopping Reasons

Due to Sorafenib became first line treatment for HCC, the designed treatment became less competitive. The company Sanofi decided not to continue to support

Limitations And Caveats

Due to Sorafenib becoming a first line treatment for HCC, the designed treatment became less competitive. The company Sanofi decided not to continue support. Study was terminated after accrual of 4 of the 32 planned patients.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID